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Abstract
Background: Undiagnosed patients with the attenuated form of mucopolysaccharidosis (MPS)
type I often have joint symptoms in childhood that prompt referral to a rheumatologist. A survey
conducted by Genzyme Corporation of 60 European and Canadian rheumatologists and pediatric
rheumatologists demonstrated that < 20% recognized signs and symptoms of MPS I or could
identify appropriate diagnosis tests. These results prompted formation of an international working
group of rheumatologists, pediatric rheumatologists, and experts on MPS I to formulate a
rheumatology-based diagnostic algorithm. The resulting algorithm applies to all MPS disorders with
musculoskeletal manifestations.
Bone and joint manifestations are prominent among most patients with MPS disorders. These life-
threatening lysosomal storage diseases are caused by deficient activity of specific enzymes involved
in the degradation of glycosaminoglycans. Patients with attenuated MPS disease often experience
diagnostic delays. Enzyme replacement therapy is now commercially available for MPS I
(laronidase), MPS II (idursulfase), and MPS VI (galsulfase).
Presentation of the hypothesis: Evolving joint pain and joint contractures in the absence of
inflammation should always raise the suspicion of an MPS disorder. All such patients should undergo
urinary glycosaminoglycan (uGAG) analysis (not spot tests for screening) in a reputable laboratory.
Elevated uGAG levels and/or an abnormal uGAG pattern confirms an MPS disorder and specific
enzyme testing will determine the MPS type. If uGAG analysis is unavailable and the patient exhibits
any other common sign or symptom of an MPS disorder, such as corneal clouding, history of hernia
surgery, frequent respiratory and/or ear, nose and throat infections; carpal tunnel syndrome, or
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heart murmur, proceed directly to enzymatic testing. Refer patients with confirmed MPS to a
geneticist or metabolic specialist for further evaluation and treatment.
Testing of the hypothesis: We propose that rheumatologists, pediatric rheumatologists, and
orthopedists consider our diagnostic algorithm when evaluating patients with joint pain and joint
contractures.
Implications of the hypothesis: Children and young adults can suffer for years and sometimes
even decades with unrecognized MPS. Rheumatologists may facilitate early diagnosis of MPS based
on the presenting signs and symptoms, followed by appropriate testing. Early diagnosis helps ensure
prompt and appropriate treatment for these progressive and debilitating diseases.
Background
Undiagnosed patients with the attenuated form of muco-
polysaccharidosis type I (MPS I) often have joint symp-
toms in childhood that prompt their referral to a
rheumatologist, orthopedist, or orthopedic surgeon.
Diagnostic delays are unfortunately common for patients
with attenuated MPS I, who can suffer for years, some-
times decades, from this progressive and debilitating dis-
ease before it is finally recognized [1-4] (Appendix). The
advent of enzyme replacement therapy (laronidase,
Aldurazyme®, Genzyme Corporation, Cambridge MS) for
MPS I in 2003, has enabled a targeted approach in the
management of attenuated MPS I. Rheumatologists and
musculoskeletal specialists are in a position to recognize
the possibility of MPS I, enabling appropriate diagnosis
and treatment of affected individuals before development
of an irreversible disease stage.
To gauge physician familiarity with the symptoms of MPS
I and experience with MPS I patients, Genzyme Corpora-
tion conducted a survey of practicing rheumatologists and
pediatric rheumatologists in Canada, France, Germany,
Italy, Spain, and the United Kingdom [4]. Among the 60
participants, only 9% indicated that they had seen an MPS
I patient in their practice; however, an additional 13%
indicated that they might have an MPS I patient in their
care on the basis of common signs and symptoms. When
presented with a description of an 8-year-old girl or a 23-
year-old woman exhibiting musculoskeletal signs of MPS
I, only 13% of pediatric rheumatologists and 19% of
rheumatologists considered MPS I in their differential
diagnosis. This percentage increased only slightly or actu-
ally declined when additional signs and symptoms of
MPS I were added to patient descriptors. Finally, when
asked what diagnostic tests should be performed when
MPS I is suspected, only 20% of the pediatric rheumatol-
ogists and none of the rheumatologists identified appro-
priate tests. The results of this survey prompted an
international working group of rheumatologists, pediatric
rheumatologists, and experts on MPS I to formulate a
rheumatology-based diagnostic algorithm for MPS I.
Although the algorithm was developed specifically for
MPS I, it is also applicable to attenuated forms of all other
MPS disorders with the exception of MPS III (Sanfilippo
syndrome), which is characterized primarily by CNS man-
ifestations [5-7]. In particular, MPS I and II (Hunter dis-
ease) have a very similar clinical presentation, although
MPS II occurs primarily in boys as it is inherited in an X-
linked recessive manner. MPS II and MPS VI (Maroteaux-
Lamy) are also now treatable with enzyme replacement
therapy [8,9].
About MPS I
MPS I is one of the more common mucopolysacchari-
doses, a family of seven inherited metabolic diseases
caused by deficient activity of various lysosomal enzymes,
resulting in the inability to metabolize certain gly-
cosaminoglycans (Table 1). In the case of MPS I, patients
have an undetectable activity of the lysosomal enzyme α-
L-iduronidase (IDUA)[10]. Lack of IDUA activity results
in progressive accumulation of the glycosaminoglycans
dermatan sulfate and heparan sulfate in lysosomes
throughout the body, leading to a multi-systemic disease.
Prominently affected organ systems include airways,
heart, viscera, skeleton, and (in the most severe cases) the
central nervous system. The disease presents across a spec-
trum of severity, and historically is categorized into three
subjectively defined phenotypes. "Hurler syndrome," the
most severe form of the disease, begins in infancy,
progresses rapidly, and is associated with profound cogni-
tive decline. Untreated children with Hurler syndrome
rarely survive beyond age 10 [11]. "Scheie syndrome," the
least severe, is characterized by onset in childhood, varia-
ble rate of progression and organ involvement, normal
intelligence, and survival to adulthood. "Hurler-Scheie
syndrome" encompasses patients with onset in early
childhood, mild to moderate CNS involvement, and an
intermediate rate of progression and organ involvement.
Clinical heterogeneity is especially prominent in the less
severe end of the spectrum, and Hurler-Scheie and Scheie
presentations are often grouped together and referred to
as "attenuated MPS I."Pediatric Rheumatology 2009, 7:18 http://www.ped-rheum.com/content/7/1/18
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Table 1: MPS Disorders Likely to be Encountered by a Rheumatologist or Orthopedist
MPS I
(Hurler, Hurler-
Scheie, Scheie)
MPS II
(Hunter)
MPS IV
(Morquio)
MPS VI
(Maroteaux-Lamy)
MPS VII
(Sly syndrome)
Deficient lysosomal 
enzyme
α-L-iduronidase Iduronate sulfatase Galactose 6-sulfatase 
or β-galactosidase
Arylsulfatase B β-Glucuronidase
Inheritance Autosomal recessive X-linked recessive 
(most patients are 
male)
Autosomal recessive Autosomal recessive Autosomal recessive
Common clinical
manifestations in
attenuated patients
(can be subtle or 
severe)
Joint involvement 
with
no inflammation
++ +  * + +
Dysostosis 
multiplex
++ +  * + +
Growth deficits + + + + +
Corneal clouding + None + + ~
History of umbilical 
and/or
inguinal hernia
++++ +
Elevated total 
urinary
glycosaminoglycan 
level† 
and/or abnormal
glycosaminoglycan 
profile
+++ § ++
Coarse facies + + + + +
Carpal tunnel 
syndrome
++~+ +
Cardiac valve 
disease
++++ +
Enzyme 
replacement 
therapy
Laronidase 
(Aldurazyme®)
Idursulfase (Elaprase®) In development Galsulfase 
(Naglazyme®)
In development
*MPS IV is characterized by distinctive and severe skeletal dysplasia, dysplastic odontoid process, and joint hyper-extendibility/ligamentous laxity.
†False negatives can occur with spot screening.
§Patients with MPS IV typically have an abnormal GAG profile, but total urinary GAG levels can be in the normal range with some methodologiesPediatric Rheumatology 2009, 7:18 http://www.ped-rheum.com/content/7/1/18
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Patients with attenuated MPS I, unlike those with the
severe, "Hurler" form of the disease, often have no obvi-
ous physical abnormalities; facial appearance is usually
normal or only subtly altered, stature can be in the normal
range, and skeletal abnormalities are often absent or sub-
clinical. Learning issues, if present, can be mild. Common
early clinical features include joint pain and stiffness, cor-
neal clouding, umbilical and/or inguinal hernia, carpal
tunnel syndrome (note that an MPS disorder is the most
frequent cause of carpal tunnel syndrome in children and
adolescents [12,13]), hearing loss, frequent ear, nose and
throat infections, and "noisy" breathing. Musculoskeletal
abnormalities that can occur later in the disease course
include progressive arthropathy, hip dysplasia, dysostosis
multiplex, spine deformities, and spinal cord compres-
sion. Cardiac valve disease is also very common.
As shown in Table 1, the major clinical manifestations of
attenuated MPS I are similar to those of MPS II, MPS VI,
and MPS VII (Sly syndrome). MPS IV, Morquio syndrome,
is characterized by a distinctive and severe skeletal dyspla-
sia, dysplastic odontoid process, and hyperextendable
joints/ligamentous laxity rather than joint contractures
[5]. All of the MPS disorders occur across a spectrum of
severity, and diagnosis is often challenging for those with
the less severe forms of the disease.
Joint Symptoms in MPS I
Joint symptoms in MPS I patients are almost universal,
and in the case of attenuated disease are often the first
symptom that brings a child to medical attention [1,2]. In
the MPS I Registry, an ongoing, observational database
that tracks natural history and outcomes of patients with
MPS I, joint contractures are reported in over 80% of
Hurler-Scheie and Scheie patients and usually precede
diagnosis [14].
The basis for the abnormal development of bone and car-
tilage seen in the MPS disorders is not fully understood.
Although the absence of clinical signs of inflammation is
a hallmark of joint involvement in the MPS disorders,
investigations conducted in animal models suggest para-
doxically that the pathophysiology of bone disease
involves inflammatory cytokines such as tumor necrosis
factor α and interleukin-1β in addition to proteins impor-
tant for lipopolysaccharide signaling (e.g., Toll-like recep-
tor 4 and lipoprotein-binding protein) [15-17].
Presentation of the Hypothesis
To aid rheumatologists and other physicians in the differ-
ential diagnosis of MPS I and other MPS disorders, a diag-
nostic algorithm is proposed (Figure 1), which was
drafted at a one-day meeting attended by all authors. Joint
contractures were chosen as a starting point in the algo-
rithm because they are an early and almost universal
symptom among MPS patients with attenuated disease. In
summary, joint pain and joint contractures in the absence
of systemic and local signs of inflammation should always
raise the suspicion of an MPS disorder, especially in con-
cert with any other common sign or symptom of MPS.
Note that in cases of juvenile idiopathic arthritis charac-
terized by "dry arthritis," joints usually lack synovial effu-
sions, but patients may display other signs of an
inflammatory process, such as frequent fevers and/or high
erythrocyte sedimentation rate [18]. In contrast, MPS
patients typically have no swelling or local inflammation
of any joints, no morning stiffness, no laboratory indica-
tors of inflammation (erythrocyte sedimentation rate, C-
reactive protein, and white blood cell counts are not ele-
vated), no response to steroids or non-steroidal anti-
inflammatory drugs, and no radiographic evidence of ero-
sive bone lesions (Figure 2 and 3). Indeed, the problems
are persistent and often progress, particularly in patients
not on enzyme therapy.
When MPS I or other MPS disorder is suspected, a urinary
glycosaminoglycan (uGAG) analysis (both quantitative
and qualitative) should be performed at a reputable labo-
ratory. We do not recommend a spot screen, as they are
inaccurate and false negatives can occur. An elevated
uGAG level is a strong indicator of an MPS disorder; how-
ever, a normal uGAG level does not rule out all forms of
MPS, some of which are best identified by an abnormal
uGAG profile [6,7,19]. An elevated uGAG level and/or an
abnormal uGAG pattern confirms the presence of an MPS
disorder and specific enzyme testing will determine the
MPS type. If comprehensive uGAG analysis is not availa-
ble, enzymatic testing should still be performed if the
patient exhibits any other common sign or symptom of an
MPS disorder, such as corneal clouding (Figure 4) or his-
tory of hernia surgery, frequent respiratory and/or ear,
nose and throat infections, carpal tunnel syndrome, or
heart murmur. Table 1 lists the specific enzyme deficiency
characteristic of each disorder. A definitive diagnosis of
MPS I is based on deficient IDUA activity in fibroblasts,
leukocytes, serum, or blood spots [20,21].
Treatment
Patients with confirmed MPS should be referred to a
geneticist or metabolic specialist for further evaluation
and treatment. All of the MPS disorders are multisystemic
and progressive and are best managed by a multidiscipli-
nary team with comprehensive followup [5,10,22]. Both
disease-specific treatment as well as symptom-based sup-
portive care are important, in addition to patient educa-
tion, genetic counseling, psychosocial support, and
physical and/or occupational therapy. MPS patients can
have significant (and often under-recognized) airway
problems and cervical spine issues such as spinal cord
compression that increase risk of anesthetic complica-
tions; thus, appropriate precautions should be taken
before any surgery.Pediatric Rheumatology 2009, 7:18 http://www.ped-rheum.com/content/7/1/18
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Diagnostic Algorithm for Attenuated Mucopolysaccharidoses Figure 1
Diagnostic Algorithm for Attenuated Mucopolysaccharidoses. *Newborn infants with the most severe form of MPS I 
(Hurler syndrome), although normal appearing, often have radiologic evidence of bone and joint abnormalities. **Note that 
overall skin texture in patients with MPS I can be thickened and rough. MPS II [6,7] and rarely MPS I [30] can be associated with 
a distinctive skin lesion consisting of white "pebbly" papules 2-10 mm in diameter, sometimes coalescing in ridges. †We recom-
mend both quantitative and qualitative (GAG profile) analysis in a reputable laboratory. False negatives can occur with spot 
screening. §See Table 1 for listing of enzyme deficiencies. Abbreviations: IDUA: α-L-iduronidase; uGAG: urinary gly-
cosaminoglycan; JIA: juvenile idiopathic arthritis; RA: rheumatoid arthritis.Pediatric Rheumatology 2009, 7:18 http://www.ped-rheum.com/content/7/1/18
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Disease-specific care for patients with attenuated MPS I
consists of enzyme replacement therapy with laronidase
(0.58 mg/100 U per kg per week). Available enzyme
replacement therapies for the other MPS diseases with
musculoskeletal manifestations are listed in Table 1. As
with any progressive metabolic disease, early initiation of
therapy that addresses the underlying pathophysiology
improves outcome, and can prevent or at least delay the
development of irreversible disease manifestations. Clini-
cal trials of laronidase in patients with attenuated MPS I
have demonstrated improved respiration, decreased
hepatomegaly, increased walking ability, enhanced joint
range of motion, and improved quality of life [23-26].
Hematopoietic stem cell transplantation (HSCT) is rec-
ommended for patients with severe MPS I, if performed
before age 2 as it can prolong life and preserve cognition,
but is not recommended for patients with attenuated MPS
I, because they have little or no cognitive involvement,
making the procedural risk-benefit ratio unacceptable
(10-15% mortality) [10]. HSCT is used much less fre-
quently in other MPS disorders and only among severely
affected patients and transplant outcome has been mixed
[7,27-29].
Testing of Hypothesis
We propose that clinicians, particularly rheumatologists,
pediatric rheumatologists, and orthopedists use our diag-
nostic algorithm when evaluating any patient with joint
pain, stiffness or contractures and no systemic and local
signs of inflammation. The index of suspicion for MPS
should be especially high if the patient also has a history
of hernia surgery, frequent respiratory infections, corneal
clouding, carpal tunnel syndrome, or cardiac valvular
abnormalities.
Physical and Radiographic Appearance of Hands in MPS I ver- sus Juvenile Idiopathic Arthritis Figure 2
Physical and Radiographic Appearance of Hands in 
MPS I versus Juvenile Idiopathic Arthritis. The images 
on the left depict typical findings in MPS I - the curled "claw 
hand," abnormal metacarpal bones, proximal widening of 
phalanges, and the V-shaped deformity of the distal ulna and 
radius, particularly evident in severe MPS I. In contrast, the 
images on the right of a child with juvenile arthritis show the 
typical joint swelling and erosive bone lesions. Photos cour-
tesy of J. Edmond Wraith, Rolando Cimaz, and Bianca Link.
Juvenile Arthritis Mucopolysaccharidosis I
Attenuated Severe
Photo: J. Edmond Wraith Photo: Rolando Cimaz
Photo: Rolando Cimaz Photo: J. Edmond Wraith Photo: Bianca Link
Spine in Attenuated MPS I Figure 3
Spine in Attenuated MPS I. Left Panel: Cervical spine 
X-ray of an adolescent with attenuated MPS I showing ossifi-
cation disturbance in the anterior part of column resulting in 
oval shaped vertebral bodies with anterior beaking and hypo-
plastic dens axis. Photo courtesy of Bianca Link. Right 
Panel: Complete spine X-ray in an adult patient with attenu-
ated MPS I showing nearly normal shaped vertebral bodies 
and gibbus deformity at the thoracolumbar junction. Note 
that lateral X-rays of the thoracolumbar spine can also reveal 
anterior beaking. Photo courtesy of Bianca Link.
Left Panel
Right PanelPediatric Rheumatology 2009, 7:18 http://www.ped-rheum.com/content/7/1/18
Page 7 of 8
(page number not for citation purposes)
Implications of Hypothesis
Attenuated MPS disorders can present a diagnostic chal-
lenge because the symptoms are often subtle and/or non-
specific. Rheumatologists, and especially pediatric rheu-
matologists, are uniquely positioned to recognize many
patients with attenuated MPS because of their characteris-
tic joint involvement. Use of the proposed diagnostic
algorithm should improve disease recognition, and ena-
ble more patients to receive appropriate treatment earlier
in the course of their disease, maximizing clinical out-
come and enhancing patient quality of life.
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Appendix
Common Misdiagnoses for MPS I Based on Joint 
Symptoms [1,2,4]
￿ Autoimmune disease
￿ Muscular dystrophy
￿ Connective tissue disease
￿ Osteogenesis imperfecta
￿ Dermato/polymyositis
￿ Polymyositis
￿ Dermatomyositis
￿ Polyneuropathy
￿ Fibromyalgia
￿ Rheumatoid arthritis
￿ Growing pains
Corneal Clouding in Patients with MPS I Figure 4
Corneal Clouding in Patients with MPS I. Corneal 
clouding is an early and almost universal sign of MPS I in both 
severe and attenuated phenotypes. It can be very marked, as 
in the right eye of the patient shown in the upper panel, or 
less obvious as in the eye shown in the lower panel. Typically, 
it is bilateral; in the patient shown in the upper panel, a cor-
neal transplant was performed in the left eye. Photos cour-
tesy of J. Edmond Wraith.Pediatric Rheumatology 2009, 7:18 http://www.ped-rheum.com/content/7/1/18
Page 8 of 8
(page number not for citation purposes)
￿ Scleroderma
￿ Juvenile idiopathic arthritis
￿ Spondyloarthritis
￿ Legg-Perthes disease
￿ Other systemic rheumatic disorder
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